{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T06:54:35Z","timestamp":1781506475391,"version":"3.54.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T00:00:00Z","timestamp":1781481600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T00:00:00Z","timestamp":1781481600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"UK National Screening Committee"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diagn Progn Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The screening pathway for sickle cell disease (SCD) in England starts with a carrier status blood test for the pregnant woman. Following a positive result, the test is offered to the biological father. Where both results are positive, further invasive testing is offered to assess the risk of SCD to the fetus. When the father is unavailable, the timely offer of further testing may be delayed and even missed, leaving the pregnant woman underinformed and limiting reproductive choice. Non-invasive prenatal testing (NIPT) presents an alternative to paternal testing and diagnostic accuracy studies of NIPT in SCD screening are required to inform utility and application. We explored the minimally acceptable sensitivity and specificity to inform such an accuracy study of NIPT.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A decision tree model was produced to identify the minimally acceptable sensitivity and specificity of NIPT. Stakeholder engagement identified a positive predictive value (PPV) equal to the paternal carrier blood test and two sensitivity\/specificity scenarios: Scenario 1 should result in\u2009&lt;\u200910 false negative diagnoses per year; Scenario 2 should result in \u2264\u20092 false negative diagnoses per year. Subsequently, the minimally acceptable sensitivity and specificity were used to calculate the sample size for a hypothetical accuracy study of NIPT in each scenario.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Scenario 1 led to a minimally acceptable sensitivity of 96.0% and specificity of 88.5% and corresponding negative predictive value (NPV) of 99.81%, PPV of 25.51% and accuracy of 88.80%. Utilising an expected prevalence of SCD of 3.94%, the resulting sample size would include 315,824 total pregnancies.<\/jats:p>\n                    <jats:p>Scenario 2 led to a minimally acceptable sensitivity of 99.0% and specificity of 88.0% and corresponding NPV of 99.95%, PPV of 25.29% and accuracy of 88.43%. The resulting sample size would include 65,509 overall pregnancies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>While the sample size calculated for each scenario is unfeasible if considering a prospective cohort study, approaches are presented to achieve realistic sample sizes. Increasing the sensitivity and specificity levels might be considered if this is likely to be achievable based on available studies, albeit limited in volume. Consideration could be given to study design mitigations that are consistent with guidance on accuracy studies in low prevalence settings.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s41512-025-00192-w","type":"journal-article","created":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T06:36:10Z","timestamp":1781505370000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Minimally acceptable criteria and required sample size for an accuracy study of non-invasive prenatal testing of sickle cell disease in screen positive women in England: results of a decision tree model"],"prefix":"10.1186","volume":"10","author":[{"given":"Vittoria","family":"Vardanega","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ania","family":"Bobrowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Ruban-Fell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James A.","family":"Doorbar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Lombardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farah","family":"Seedat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvonne","family":"Daniel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Hogan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariska M. G.","family":"Leeflang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathy","family":"Mann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Schuh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Marshall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,15]]},"reference":[{"key":"192_CR1","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1136\/archdischild-2013-303773","volume":"100","author":"S Chakravorty","year":"2015","unstructured":"Chakravorty S, Williams TN. Sickle cell disease: a neglected chronic disease of increasing global health importance. Arch Dis Child. 2015;100:48\u201353.","journal-title":"Arch Dis Child"},{"key":"192_CR2","unstructured":"National Health Service. National Haemoglobinopathy Registry Annual Report. Available at: https:\/\/nhr.mdsas.com\/wp-content\/uploads\/2022\/03\/NHR_DataReport2021.pdf .Accessed 8 July 2024."},{"key":"192_CR3","unstructured":"National Institute for Health and Care Excellence. How common is sickle cell disease? Available at: https:\/\/cks.nice.org.uk\/topics\/sickle-cell-disease\/background-information\/prevalence\/. Accessed 8 July 2024."},{"key":"192_CR4","unstructured":"GOV.UK. Sickle cell and thalassaemia (SCT) screening: programme overview. Available at: https:\/\/www.gov.uk\/guidance\/sickle-cell-and-thalassaemia-screening-programme-overview#conditions-screened-for Accessed 8 July 2024."},{"key":"192_CR5","unstructured":"GOV.UK. The UK NSC recommendation on Sickle cell and Thalassaemia screening in pregnancy. Available at: https:\/\/view-health-screening-recommendations.service.gov.uk\/sickle-cell-and-thalassaemia\/. Accessed 8 July 2024."},{"key":"192_CR6","unstructured":"GOV.UK. Population screening programmes. Available at https:\/\/www.gov.uk\/government\/collections\/population-screening-programmes-document-collection. Accessed 8 July 2024."},{"key":"192_CR7","unstructured":"GOV.UK. SCT screening: handbook for antenatal laboratories. Available at: https:\/\/www.gov.uk\/government\/publications\/sct-screening-handbook-for-antenatal-laboratories. Accessed 8 July 2024."},{"key":"192_CR8","unstructured":"Public Health England. Sickle cell and thalassaemia screening: data report 2019 to 2020. Available at: https:\/\/www.gov.uk\/government\/publications\/sickle-cell-and-thalassaemia-screening-data-report-2019-to-2020\/sickle-cell-and-thalassaemia-screening-data-report-2019-to-2020. Accessed 8 July 2024."},{"key":"192_CR9","first-page":"215","volume":"70","author":"J Beta","year":"2018","unstructured":"Beta J, Lesmes-Heredia C, Bedetti C, et al. Risk of miscarriage following amniocentesis and chorionic villus sampling: a systematic review of the literature. Minerva Ginecol. 2018;70:215\u20139.","journal-title":"Minerva Ginecol"},{"key":"192_CR10","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1111\/bjh.16529","volume":"190","author":"J van Campen","year":"2020","unstructured":"van Campen J, Silcock L, Yau S, et al. A novel non-invasive prenatal sickle cell disease test for all at-risk pregnancies. Br J Haematol. 2020;190:119\u201324.","journal-title":"Br J Haematol"},{"key":"192_CR11","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1182\/blood.2019002099","volume":"134","author":"A Cutts","year":"2019","unstructured":"Cutts A, Vavoulis DV, Petrou M, et al. A method for noninvasive prenatal diagnosis of monogenic autosomal recessive disorders. Blood. 2019;134:1190\u20133.","journal-title":"Blood"},{"key":"192_CR12","doi-asserted-by":"publisher","unstructured":"Vardanega V, Bobrowska A, Ruban-Fell B, et al. Modelling the Cost-Effectiveness of Non-invasive Prenatal Testing in the English Sickle Cell and Thalassaemia Screening Pathway. Diagn Progn Res. 2026;10. https:\/\/doi.org\/10.1186\/s41512-025-00212-9.","DOI":"10.1186\/s41512-025-00212-9"},{"key":"192_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s41512-019-0069-2","volume":"3","author":"DA Korevaar","year":"2019","unstructured":"Korevaar DA, Gopalakrishna G, Cohen JF, et al. Targeted test evaluation: a framework for designing diagnostic accuracy studies with clear study hypotheses. Diagnostic and prognostic research. 2019;3:1\u201310.","journal-title":"Diagnostic and prognostic research"},{"key":"192_CR14","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-024324","volume":"9","author":"D Bevan","year":"2019","unstructured":"Bevan D, White A, Marshall J, et al. Modelling the effect of the introduction of antenatal screening for group B Streptococcus (GBS) carriage in the UK. BMJ Open. 2019;9: e024324.","journal-title":"BMJ Open"},{"key":"192_CR15","unstructured":"Sian Taylor-Phillips KF, Julia Geppert, Jason Madan, Olalekan Uthman, Adeola Agbebiya, Angus Clarke, Siobhan Quenby, Aileen Clarke. Systematic review and cost-consequence assessment of cell-free DNA testing for T21, T18 and T13 in the UK 2015. Available at: https:\/\/view-health-screening-recommendations.service.gov.uk\/edwards-syndrome\/. Accessed 15 October 2025."},{"key":"192_CR16","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1002\/lary.23943","volume":"123","author":"L Rudmik","year":"2013","unstructured":"Rudmik L, Drummond M. Health economic evaluation: important principles and methodology. Laryngoscope. 2013;123:1341\u20137.","journal-title":"Laryngoscope"},{"key":"192_CR17","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1148\/radiol.12120527","volume":"267","author":"EA Ochodo","year":"2013","unstructured":"Ochodo EA, de Haan MC, Reitsma JB, et al. Overinterpretation and misreporting of diagnostic accuracy studies: evidence of \u201cspin.\u201d Radiology. 2013;267:581\u20138.","journal-title":"Radiology"},{"key":"192_CR18","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1056\/NEJMoa1407349","volume":"372","author":"ME Norton","year":"2015","unstructured":"Norton ME, Jacobsson B, Swamy GK, et al. Cell-free DNA analysis for noninvasive examination of trisomy. N Engl J Med. 2015;372:1589\u201397.","journal-title":"N Engl J Med"},{"key":"192_CR19","unstructured":"Nuffield Council on Bioethics. Non-invasive prenatal testing: ethical issues. Available at: https:\/\/www.nuffieldbioethics.org\/assets\/pdfs\/NIPT-ethical-issues-full-report.pdf . Accessed 8 July 2024."},{"key":"192_CR20","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1136\/bmj.38793.637789.2F","volume":"332","author":"LM Bachmann","year":"2006","unstructured":"Bachmann LM, Puhan MA, Ter Riet G, et al. Sample sizes of studies on diagnostic accuracy: literature survey. BMJ. 2006;332:1127\u20139.","journal-title":"BMJ"},{"key":"192_CR21","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1002\/mpr.1504","volume":"25","author":"BD Thombs","year":"2016","unstructured":"Thombs BD, Rice DB. Sample sizes and precision of estimates of sensitivity and specificity from primary studies on the diagnostic accuracy of depression screening tools: a survey of recently published studies. Int J Methods Psychiatr Res. 2016;25:145\u201352.","journal-title":"Int J Methods Psychiatr Res"},{"key":"192_CR22","doi-asserted-by":"crossref","unstructured":"Holtman GA, Berger, M. Y., Burger, H., Deeks, J. J., Donner-Banzhoff, N., Fanshawe, T. R., Koshiaris, C., Leeflang, M. M., Oke, J. L., Perera, R., Reitsma, J. B., & Van den Bruel, A. Development of practical recommendations for diagnostic accuracy studies in low-prevalence situations. Journal of Clinical Epidemiology 2019:38\u201348.","DOI":"10.1016\/j.jclinepi.2019.05.018"},{"key":"192_CR23","doi-asserted-by":"crossref","unstructured":"Buderer NM. Statistical methodology: I. Incorporating the prevalence of disease into the sample size calculation for sensitivity and specificity. Acad Emerg Med 1996;3:895\u2013900.","DOI":"10.1111\/j.1553-2712.1996.tb03538.x"},{"key":"192_CR24","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.jbi.2014.02.013","volume":"48","author":"K Hajian-Tilaki","year":"2014","unstructured":"Hajian-Tilaki K. Sample size estimation in diagnostic test studies of biomedical informatics. J Biomed Inform. 2014;48:193\u2013204.","journal-title":"J Biomed Inform"}],"container-title":["Diagnostic and Prognostic Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41512-025-00192-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41512-025-00192-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41512-025-00192-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T06:36:16Z","timestamp":1781505376000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s41512-025-00192-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,15]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["192"],"URL":"https:\/\/doi.org\/10.1186\/s41512-025-00192-w","relation":{},"ISSN":["2397-7523"],"issn-type":[{"value":"2397-7523","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,15]]},"assertion":[{"value":"12 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"As no patients were involved in the study, ethical approval was not required (not applicable).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"S. Lombardo and J. Marshall are employed by the UK National Screening Committee, hosted by Department of Health and Social Care. Author F. Seedat was employed by the UK National Screening Committee until October 2022. Her affiliation is now with St. George\u2019s University of London, Cranmer Terrace, London SW17 0RE, UK. A. Bobrowska is employed by Costello Medical and is a member of the Research and Methodology Group at the UK National Screening Committee. M.M.G. Leeflang is a member of the standing committee on perinatal screening for the Health Council of the Netherlands, with compensation to the Department of Epidemiology and Data Science, Amsterdam University Medical Centers, University of Amsterdam, for working hours lost due to committee activities.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"18"}}